Draupnir Bio, a Copehagen, Denmark-based biotechnology firm harnessing the pure equipment of the lysosome to develop oral, small molecule degraders of extracellular disease-causing proteins, raised €12M in Seed funding.
Backers included MP Healthcare and EIFO and present traders, Gilde Healthcare Companions, Inkef Capital and Novo Holdings.
The corporate intends to make use of the funds to additional develop its risk-diversified preclinical pipeline of oral, small molecule protein degraders, which have been confirmed in opposition to targets which can be validated and people which have been historically tough to drug.
Led by CEO Andrew Hotchkiss, Draupnir Bio is biotechnology firm growing oral, small molecule degraders of extracellular disease-causing proteins – the subsequent frontier of focused protein degradation (TPD), a quickly rising subject that exploits a cell’s personal destruction equipment to sort out disease-causing proteins which have traditionally been extremely difficult to focus on with typical therapies. It was spun-out from Aarhus College, Denmark and the Max-Planck Society.
FinSMEs
22/07/2024
